News Release

Diabetes medicine decreased cardiovascular risk in adults with chronic kidney disease

American Heart Association Scientific Sessions 2022, Abstract 19464

Reports and Proceedings

American Heart Association

Embargoed until 5:26 p.m. CT/6:26 p.m. ET, Sunday, Nov. 6, 2022

CHICAGO, Nov. 6, 2022 — SGLT-2 inhibitors, a type of diabetes medicine, decreased cardiovascular risk among adults with chronic kidney disease, according to late-breaking research presented today at the American Heart Association’s Scientific Sessions 2022. The meeting, held in person in Chicago and virtually, Nov. 5-7, 2022, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science.

“Many studies of empagliflozin and other similar medicines called SGLT-2 inhibitors (sodium-glucose co-transporter-2 inhibitors) have demonstrated that these medicines are safe for people with Type 2 diabetes,” said co-principal investigator David Preiss, Ph.D., associate professor in the Medical Research Council Population Health Research Unit at the University of Oxford, Oxford Population Health in the U.K. “And we now have very good evidence that they lower the chance of dying from vascular disease or being hospitalized for heart failure among people with chronic kidney disease, heart failure, or Type 2 diabetes and cardiovascular disease. We therefore hope that SGLT-2 inhibitors may be used widely to treat people with these conditions in many countries.”

The researchers combined the results from 13 major clinical trials of SGLT-2 inhibitors to consider the effects on kidney disease progression, acute kidney injury and cardiovascular death or hospitalization for heart failure, in participants with or without Type 2 diabetes. According to Preiss, the analysis confirmed important benefits of SGLT-2 inhibitors on both major cardiovascular and kidney disease outcomes:

  • SGLT-2 inhibitors reduced the risk of cardiovascular death by 14%, with similar results among participants with or without Type 2 diabetes.
  • SGLT-2 inhibitors also reduced the risk of cardiovascular death or hospitalization for heart failure by 23%, with similar results among the participants with or without Type 2 diabetes.
  • The risk of kidney disease progression was reduced by 37% overall, again with similar effects among participants regardless of Type 2 diabetes status.
  • Based on the trial data, for every 1,000 participants with heart failure treated for a year, 34 with diabetes and 22 without diabetes avoided cardiovascular death or hospitalization for heart failure.
  • For every 1,000 participants with chronic kidney disease treated for a year, 11 with diabetes and 15 without diabetes avoided worsening kidney disease.

The meta-analysis included results from the EMPA-KIDNEY Trial, the largest study to assess the use of SGLT-2 inhibitors in participants with chronic kidney disease. Previous research linked the medicine with a decreased risk of hospitalization for heart failure and a decreased risk of worsening kidney disease among people with Type 2 diabetes. “What remained unclear is whether this medicine may have the same protective effect among people not diagnosed with Type 2 diabetes,” Preiss said.

EMPA-KIDNEY researchers enrolled 6,609 study participants in eight countries: Germany, the United States, the United Kingdom, China, Malaysia, Japan, Canada and Italy. Participants’ average age was 64 years, and more than half were white adults, 36% were Asian adults and 4% were Black adults. All participants had evidence of kidney disease for at least 3 months; more than 25% had cardiovascular disease; and slightly less than half had Type 2 diabetes. Between May 2019 and April 2021, participants were randomly assigned to empagliflozin or a placebo. Follow-up was for an average of two years.

Results of the EMPA-KIDNEY trial, published two days ago on November 4, 2022, showed that among the participants in the empagliflozin group, the risk of worsening kidney disease and death from cardiovascular disease decreased by 28%, with similar benefits for participants with or without Type 2 diabetes. The rate of cardiovascular events was lower than anticipated. Though the reduction in major cardiovascular events with empagliflozin treatment was not statistically significant in the trial, the results for these outcomes were entirely consistent with results from other trials.

“Our results suggest that SGLT-2 inhibitors such as empagliflozin should be offered to all adults who may benefit from the treatment, to reduce the risk of kidney disease progression and cardiovascular complications in people with chronic kidney disease, regardless of whether they have Type 2 diabetes or not,” Preiss said.

Co-authors are William Herrington, M.D., and Richard Haynes, D.M., on behalf of the Oxford Population Health Renal Studies Group and the SGLT2 Meta-analysis Cardio-renal Trialists’ Consortium (SMART-C). Authors’ disclosures are listed in the abstract.

The study was funded by core funding to the Medical Research Council Population Health Research Unit at the University of Oxford from the UK Medical Research Council. EMPA-KIDNEY was funded by Boehringer Ingelheim and Eli Lilly and Company.

Statements and conclusions of studies that are presented at the American Heart Association’s scientific meetings are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. Abstracts presented at the Association’s scientific meetings are not peer-reviewed, rather, they are curated by independent review panels and are considered based on the potential to add to the diversity of scientific issues and views discussed at the meeting. The findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.

The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers and the Association’s overall financial information are available here.

Additional Resources:

The American Heart Association’s Scientific Sessions 2022 is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science. The 3-day meeting will feature more than 500 sessions focused on breakthrough cardiovascular basic, clinical and population science updates occurring Saturday through Monday, November 5-7, 2022. Thousands of leading physicians, scientists, cardiologists, advanced practice nurses and allied health care professionals from around the world will convene virtually to participate in basic, clinical and population science presentations, discussions and curricula that can shape the future of cardiovascular science and medicine, including prevention and quality improvement. During the three-day meeting, attendees receive exclusive access to more than 4,000 original research presentations and can earn Continuing Medical Education (CME), Continuing Education (CE) or Maintenance of Certification (MOC) credits for educational sessions. Engage in Scientific Sessions 2022 on social media via #AHA22. 

About the American Heart Association

The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1. 

###

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.